1-855-378-42281-855-378-4228
One of the out-patient treatment options for individuals in Youngtown who are battling with opioid dependence and addiction is opioid maintenance therapy. Licensed centers and doctors are authorized to administer specific medications to opioid addicted individuals, many of which are opioids themselves and are addictive. With low enough amounts the individual doesn't experience being high but also does not have severe cravings and isn't experiencing opioid withdrawal. Methadone is the first med tried for this purpose, but there are a few more options currently to choose from.
Methadone is an opioid and can be taken at an outpatient clinic licensed to dispense the med, which is taken daily in liquid or pill form. The price of the drug is around one hundred and fifty dolloars a month. Buprenorphine is also an opioid-based med, and is in pill form often taken one day on, one day off. But different from Methadone which can only be dispensed in highly structured clinics, Buprenorphine can be and is prescribed and administered in doctor's offices. The cost monthly of buprenorphine is approximately three hundred dollars per month for the generic version of the med. There is also a type of buprenorphine that contains the ingredient naloxone, which is a med which reverses the effects of opiates. A person taking this formulation, also known as Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It too is taken every day, and costs around $450 a month. Naltrexone is another med taken in opioid maintenance therapy, but unlike the other drugs mentioned it's an opiate blocker and isn't an opiate. A person has the choice to take this medication as a monthly injection, and that is called Vivitrol. As an opioid blocker, it prevents a person from experience being high from opioids, and in turn lowers the risk associated with relapse. This daily shot costs in the range of $1000 to $1200 /month.
For All Drug and Alcohol Rehab Facilities In Youngtown, Click Here.
